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Abstract
Background: Depression is a major challenge worldwide, with significant increasing personal, economic, and
societal costs. Although empirically supported treatments have been developed, they are not always available for
patients in routine clinical care. Therefore, we need effective and widely accessible strategies to prevent the onset
of the very first depressive symptoms. Mental health apps could prove a valuable solution for this desideratum.
Although preliminary research has indicated that such apps can be useful in treating depression, no study has
attempted to test their utility in preventing depressive symptoms. The aim of this exploratory study is to contrast
the efficacy of a smartphone app in reducing cognitive vulnerability and mild depressive symptoms, as risk factors
for the onset of depression, against a wait-list condition. More specifically, we aim to test an app designed to (1)
decrease general cognitive vulnerability and (2) promote engagement in protective, adaptive activities, while (3)
counteracting (through gamification and customization) the tendency of premature dropout from intervention.
Methods/design: Romanian-speaking adults (18 years and older) with access to a computer and the Internet and
who own a smartphone are included in the study. Two parallel randomized clinical trials are conducted: in the first
one, 50 participants free of depressive symptoms (i.e., who obtain scores ≤4 on the Patient Health Questionnaire,
PHQ-9) will be included, while in the second one 50 participants with minimal depressive symptoms (i.e., who
obtain PHQ-9 scores between 5 and 9) will be included. Participants undergoing therapy, presenting with substance
abuse problems, psychotic symptoms, and organic brain disorders, or serious legal or health issues that would prevent
them from using the app, as well as participants reporting suicidal ideation are excluded. Participants randomized to
the active intervention will autonomously use the smartphone app for 4 weeks, while the others will be given access
to the app after 4 weeks from randomization. The primary outcomes are (1) cognitive vulnerability factors as defined
within the cognitive behavioral therapy (CBT) paradigm (i.e., dysfunctional cognitions, irrational beliefs, and negative
automatic thoughts) (for the first trial), and (2) level of depressive symptomatology (for the second trial). The app
includes self-help materials and exercises based on CBT for depression, presented in a tailored manner and
incorporating gamification elements aimed at boosting motivation to use the app.
Discussion: This study protocol is the first to capitalize on the ubiquity of smartphones to large-scale dissemination of
CBT-based strategies aimed at preventing depression in non-clinical populations.
Trial registration: ClinicalTrials.gov: NCT02783118. Registered on 26 May 2016.
Keywords: Depression, Prevention, Protocol, Randomized trial, CBT, Smartphone app
* Correspondence: giosan@outlook.com
1Department of Clinical Psychology and Psychotherapy, Babeș-Bolyai
University, Cluj-Napoca, Romania
2Berkeley College, New York, NY, USA
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Giosan et al. Trials  (2016) 17:609 
DOI 10.1186/s13063-016-1740-3
Background
About 350 million people of all ages are affected by de-
pression worldwide [1]. In 2008, the World Health
Organization (WHO) estimated depression to be the
third largest contributor to the global disease burden
(GDB) globally and the number one contributor to dis-
ease burden in developed countries [2]. In 2010, de-
pression was estimated to be the second largest
contributor to GDB [3] and, by 2030, it is expected to
become its leading contributor [4].
In the USA alone, depression costs $81 billion [5], while
in Europe it reaches about €118 billion per year [6, 7].
Although effective treatments for this condition do
exist [8, 9], they do not seem to help in decreasing the
prevalence of depression or the associated GDB [10–12].
One of the most important factors contributing to this
reality is the fact that fewer than half of those in need of
treatment (and in many countries, fewer than 10%) re-
ceive adequate care [1]. Some reasons for this are the
limited availability of adequately trained therapists,
stigma, or logistical costs [13, 14]. Thus, increasing
treatment accessibility for the affected people can have
the potential to reduce the GDB associated with
depression.
Besides increasing the treatment availability for
people experiencing depression, it is also very import-
ant to prevent the development of depressive symp-
toms. Subthreshold depression has been shown to
predict the onset of full-blown depressive episodes [15].
In addition, research shows that about 80% of people
who suffer a first major depressive episode will have at
least one more [16], with a lifetime average of four epi-
sodes [17]. Even when successfully treated, depressive
symptoms are recurrent in about 40% of cases within
the first 2 years after treatment [18]. If we consider that
(1) although antidepressant medication is effective, only
50–70% of patients respond to it [19], and (2) response
rates to cognitive behavioral therapy (CBT), one of the
most empirically validated psychological treatments for
depression, are also around 60% for moderate to severe
depression [20], preventing depressive symptoms —
along with striving for innovative strategies to increase
the efficacy of the available treatments — becomes
critical.
Framework and rationale of the study
Depression prevention efforts represent a global priority
[21]. A range of interventions, including educational,
psychotherapeutic, pharmacological, and lifestyle and
nutritional approaches, has been shown to have some
utility in preventing the development of this condition
[22, 23]. However, considering the global challenge
raised by depression, there is a need to develop strategies
that produce more enduring preventative effects [21].
Using insights from the theories at the basis of the best
empirically supported psychological treatments available
nowadays, such strategies should comprehensively target
(1) cognitive factors such as negative attitudes or cogni-
tive inflexibility [24–27], and (2) social stressors and
behavioral factors that can activate and/or exacerbate
depressive symptoms [21]. In addition, innovative
methods designed to facilitate the efficient implementa-
tion and dissemination of evidence-based prevention
strategies are needed. Cuijpers et al. [21] suggested that
the incorporation of new media, such as e-mental health
programs and smartphone solutions, in prevention strat-
egies could prove invaluable in facilitating large-scale
implementation of prevention strategies. A similar rec-
ommendation has also been advanced by the WHO,
which, in its Mental Health Action Plan 2013–2020, ad-
vises ”the promotion of self-care, for instance, through
the use of electronic and mobile health technologies”
[28].
Recent advances in mobile technology and Internet
use have resulted in a niche industry for mental health
apps, especially for depression. Searching for “depres-
sion” in the Apple Store or Google Apps Store yields
hundreds of hits (apps) related to this condition, cover-
ing aspects such as measuring depressive symptoms,
tracking mood, helping people to think more positively
or expressing their gratitude on a regular basis, monitor-
ing dysfunctional thoughts and identifying distorted
thinking patterns, challenging dysfunctional thoughts,
promoting more diversified activity patterns, and so on.
However, how useful they are in terms of preventing or
ameliorating depressive symptoms has yet to be estab-
lished. Preliminary findings showed promising results in
reducing subthreshold or mild to moderate depression
[29–34]. Still, such studies are small (pilot studies) and
few in number, and have not been replicated [35].
The evidence supporting the use of such apps is build-
ing up, but additional consistent experimental work is
needed before we can draw clear conclusions. To our
knowledge, no formalized study has attempted to test
the utility of smartphone apps in preventing depression.
Targeting risk factors for depression, such as cognitive
vulnerability [27, 36, 37] and subthreshold depressive
symptomatology [15], could represent a first step in
building well-informed preventative online programs for
this condition (see also [38]).
Objectives
The aim of this exploratory study is to test a newly de-
veloped app for decreasing cognitive vulnerability in the
general adult population, and, respectively, reducing
minimal symptoms of depression. To this end, two sam-
ples of participants will be recruited: (1) participants free
of depressive symptoms, and (2) participants presenting
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with mild depression symptoms. Within each sample,
the participants will be randomized to an active group
(i.e., a group receiving preventive intervention) and to a
wait-list control, respectively. The clinical utility of the
application will be assessed by comparing randomized
group scores within each sample type with respect to (1)
depressive symptom level, (2) negative and positive ef-
fects, (3) satisfaction with life, and (4) behavioral and
cognitive vulnerability factors involved in the onset of
depression.
This study will capitalize on one of the main advan-
tages of smartphones, namely broad accessibility. Sim-
ply, through this app, we aim to target the majority of
smartphone owners, in an attempt to (1) remit min-
imal depressive symptoms (to prevent their escalation),
(2) decrease general cognitive vulnerability for depres-
sion and promote protective behaviors, even in the
absence of any symptoms, and (3) reduce general
negative effect and increase satisfaction with life. This
initiative is congruent with recent recommendations in
the literature [39], as well as with basic CBT principles
and empirical evidence, which indicate that supporting
individuals in coping with non-clinical psychological
distress can prevent symptoms from reaching clinical
significance [40, 41]. In addition, this app is designed
to promote continuous engagement, by incorporating
tailoring, customization, and gamification elements,
aimed at nurturing intrinsic motivation to use the app.
Previous data show that one of the main problems
with computerized CBT-based interventions is prema-
ture dropout [42–44]. Therefore, though effective and
largely accessible [45, 46], these interventions often do
not reach their maximum potential because users pre-
maturely give up using them.
Borrowing from CBT principles, with a therapeutic
package inspired from rational emotive behavior therapy
(REBT) [47, 48], a new application (app) has been devel-
oped and will be tested to examine its benefits in decreas-
ing cognitive vulnerability and reducing mild depressive
symptomatology as risk factors for depression.
Methods/design
Trials design
These are two-arm, parallel-group, randomized con-
trolled exploratory trials examining the effects of an
mHealth intervention, developed to decrease cognitive
vulnerability and reduce mild depressive symptomatol-
ogy, compared to wait-list control in people with no
symptoms (study 1) and people with mild symptoms
(study 2). The participants in the mHealth condition will
be followed up for 12 months, and those in the wait-list
control group will receive the intervention after they
have completed the post-intervention assessment at
4 weeks. The design of the trials is similar to and
compliant with the Consolidated Standards of Reporting
Trials (CONSORT) guidelines [49] and with the Stand-
ard Protocol Items: Recommendations for Interventional
Trials (SPIRIT) statement 2013 [50] (see also Additional
file 1: SPIRIT checklist and schedule of enrollment, in-
terventions, and assessments).
General description of the tested application
The app to be tested, available for download for iOS and
Android, has the following features:
1. Profile and overview section: The first screen of the
application (see Fig. 1) after the login summarizes
the information about the user’s activity in a simple
and attractive format. On this screen, the users can
choose and personalize an avatar and check the
current “Energy” level reached within the application
(see details below).
As non-depressed users could be less motivated
to use an app designed for clinical use than people
suffering from depression, it is important to keep
them interested. To this end, the app incorporates
an attractive design in both the visual presentation
and flow of activities [51, 52]. Borrowing from
gamification strategies [53], the app integrates two
graphical representations similar to role-play games:
Energy and Level. ”Energy” represents a percentage
value that decreases over time if the app is not used.
The incentive is to keep the Energy level as close
to 100% as possible. Reading articles, completing
exercises, and filling out questionnaires are all
rewarded with an increase in Energy. ”Level” represents
the user’s progress through the educational articles —
reading each article increases the Level by 1. The goal
is to reach the maximum level (i.e., Level 12). This
overview also includes a chart representing the user’s
progress in improving his/her mood over time,
measured via a scale in the evaluation section
(described below).
2. Psychoeducation section: This section contains
articles and self-help materials covering topics
such as the causes of depression, the impact of
dysfunctional thinking patterns and unproductive
behaviors, healthy and unhealthy negative emotions,
as well as a series of educational videos about
relaxation techniques.
3. Exercises: The application contains a series of
guided cognitive restructuring exercises, following
the ABCDE model of emotional disturbance [48,
54]. These exercises are based on a model where
each emotion is assigned to several activated events
and the specific underlying rational/irrational beliefs
— so that the user is automatically guided through
rational thinking patterns, without the need for
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therapist feedback (see Fig. 2). This is an important
aspect of prevention programs, as easy access and
“non-consumable” services could be easily provided
to a great number of users [38]. Completing each
activity and exercise is rewarded graphically through
a notification and an increase of the Energy
percentage.
4. Evaluation section: Without leaving the application,
the user can fill out questionnaires related to the
study being conducted, along with a mood
inventory. The mood inventory updates the
progress graph on the profile section, described
earlier. Whenever a new evaluation is due, the user
is notified and rewarded with more Energy after
completing it.
5. Messages section: Each week the users are
encouraged, via automated messages, to read
articles and use the exercises available. They are
also reminded to complete that week’s assessment.
Moreover, this section allows them to send messages
to the research team regarding technical difficulties
or other obstacles encountered in using the
application’s interface.
Study setting
The study population consists of Romanian adults with
(1) no depressive symptomatology (first sample) or (2)
with mild depressive symptomatology (second sample).
The study is being implemented through the Babeș-
Bolyai University, Cluj-Napoca, Romania.
Eligibility criteria
Inclusion criteria for the first trial Healthy Romanian-
speaking adults (18 years or older) with access to a com-
puter, a smartphone (Android or iOS), and the Internet
are included in the study. The Structured Clinical Inter-
view for DSM-IV (SCID) [55], specifically the Overview
module, will be used to determine the general clinical
status of the participants. A clinical psychologist will
conduct a short interview aimed to screen for exclusion
criteria (see below). Information on drug use and phys-
ical and psychological treatment status (past and
present) will be collected. In addition, to be included in
the study, participants should report a Patient Health
Questionnaire (PHQ-9) score no greater than 4.
Exclusion criteria for the first trial Participants under-
going therapy (i.e., medication and/or psychotherapy),
presenting with substance abuse problems, psychotic
symptoms, organic brain disorders (e.g., dementia),
self-injury or harming others, or serious legal or health
issues that would prevent them from using the app, as
well as participants reporting scores greater than 1 to
Question 9 (suicidal ideation) on the PHQ-9 [56] are
excluded.
Inclusion and exclusion criteria for the second trial
The inclusion criteria for the second trial will be the
same as those for the first trial, except for the PHQ-9
cut-off. More specifically, to be included in the trial, par-
ticipants should obtain a PHQ-9 score above 4, but no
larger than 9. Exclusion criteria for the second trial are
identical to those for the first trial.
Study conditions: the mHealth intervention
The app being tested has two main components: courses
and exercises. (1) Courses represent the psychoeduca-
tional and therapeutic background of the program and
include information on the following topics: depression,
psychological vulnerability, CBT, healthy and unhealthy
negative emotions, rational and irrational thoughts, how
Fig. 1 App screenshot showing an example of the profile and
overview section
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behaviors contribute to depression, sleep hygiene, social
support, and relaxation techniques. (2) Exercises use the
information presented in the courses and follow the
structure of a regular therapy session and/or therapeutic
homework.
The following exercises are included in the app:
1. The Emotional Pulse exercise registers the
user’s current activity and emotions
(healthy or unhealthy).
2. The Sticky Notes exercise consists of a series of
tasks targeting behavioral activation (e.g., setting
goals, building a list of rewards/pleasant activities).
3. The Find Irrational Thoughts exercise helps to
identify thoughts behind the emotions found
with the Emotional Pulse exercise.
4. The Change Irrational Thoughts exercise challenges
negative/irrational thinking behind unhealthy
emotions and replaces it with healthy, flexible,
and functional thoughts.
The app can be used standalone, i.e., independently by
healthy or mildly depressed participants, without therap-
ist guidance.
The wait-list control group
Participants in the delayed intervention group are placed




For the first trial, involving a healthy sample of partici-
pants, cognitive vulnerability factors as defined within the
CBT paradigm (i.e., dysfunctional cognitions, irrational
beliefs, and negative automatic thoughts) [24–26] con-
stitute the primary outcomes. For the second trial,
involving a sample of mildly depressed participants, the
level of depressive symptomatology constitutes the pri-
mary outcome.
Secondary outcomes
For the first trial, the level of depressive symptomatol-
ogy, the general positive and negative effects, and satis-
faction with life constitute the secondary outcomes.
Besides depressive symptomatology, emotionality and
quality of life outcomes have been included to assess the
efficacy of the application on a broader spectrum of psy-
chological variables. For the second trial, the general
Fig. 2 App screenshots showing the “Find irrational beliefs exercise”
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positive and negative effects and satisfaction with life
constitute the secondary outcomes.
Other outcomes
For the first trial, behavioral activation and/or avoidance
as possible predictors of the outcomes will be examined.
For the second trial, dysfunctional cognitions, irrational
beliefs, and negative automatic thoughts (conceptualized
as mechanisms of change) and behavioral activation
and/or avoidance will be considered as possible predic-
tors of the outcomes.
Satisfaction with the application and data regarding
the app usage are also assessed in both trials.
The instruments used for each of the above-mentioned
outcomes are presented below.
Screening measures
The Overview module of the SCID [55] will be used to
determine the general clinical status of the participants.
Information on drug use and physical and psychological
treatment status (past and present) will be collected.
The SCID has been adapted for use on the Romanian
population [57].
The PHQ-9 [56] is a nine-question instrument de-
signed to correspond to the Diagnostic and Statistical
Manual of Mental Disorder, 4th edition, Revised Text
(DSM-IV-TR) [58] diagnostic criteria for major depres-
sive disorder. Respondents rate the items from 0 to 3
according to the frequency of their experience over the
previous 2-week period (0: not at all; 3: nearly every
day). The score can then be interpreted as indicating
the depression severity (no depression, mild, moderate,
moderately severe, or severe depression). The PHQ-9
has been adapted into Romanian for the purposes of
the current study.
Measures of primary, secondary, and other outcomes
The level of depressive symptomatology is assessed with
the Center for Epidemiologic Studies Depression Scale-
Revised (CESD-R) [59, 60]. The CESD-R is a 20-item
self-report instrument which measures symptoms of
depression in nine different categories: sadness (dys-
phoria), loss of interest (anhedonia), appetite, sleep,
thinking/concentration, guilt (worthlessness), tiredness
(fatigue), movement (agitation), and suicidal ideation.
Participants rate each item on a five-point Likert scale,
from 0 (not at all or less than one day) to 4 (nearly
every day for 2 weeks) to indicate how they felt or be-
haved during the last week or so. The Total CESD-R
Score is calculated as a sum of responses to all 20 ques-
tions. The CESD-R exhibited good psychometric prop-
erties, including high internal consistency, strong factor
loadings, and theoretically consistent convergent and
divergent validity with anxiety, schizotypy, and positive
and negative effects [61]. The CESD-R has been
adapted to Romanian for the purposes of the current
study.
The Positive and Negative Affect Scale (PANAS) [62] is
a 20-item self-report questionnaire designed to assess
mood. It consists of 10 items that address positive affect
(PA) and 10 items that address negative affect (NA). Par-
ticipants rate each item on a five-point Likert scale, from
1 (very slightly/not at all) to 5 (extremely) to indicate
how they felt during the indicated timeframe. The
PANAS can be used to assess mood on various time
scales by altering the instructions. For the purposes of
this study, we have used a 2-week timeframe. The valid-
ity and internal consistency of the PANAS are good,
with test–retest reliability being the highest for the
“general” temporal instruction. The PANAS has been
used previously on the Romanian population and was
found to have adequate psychometric properties [63, 64].
Satisfaction with Life (SWL) [65] is a five-item scale
designed to measure global cognitive judgements of
one’s life satisfaction. Participants rate each of the five
items using a seven-point scale that ranges from 7
(strongly agree) to 1 (strongly disagree). The SWL has
been shown to be a valid and reliable measure of life
satisfaction which can be used with a wide range of age
groups [66, 67]. The SWL scale has been adapted to
Romanian for the purposes of the current study.
The Dysfunctional Attitude Scale (DAS) [68] was de-
signed to measure the intensity of dysfunctional atti-
tudes that, according to the cognitive theory of
depression [25], contribute to vulnerability for depres-
sion. For the purpose of our study, we used the short
form of this scale. The Dysfunctional Attitude Scale -
Short Form (DAS-SF) [69] consists of two subscales:
“dependency” (6 items) and “perfectionism/performance
evaluation” (11 items). The 17 items are rated on a
seven-point Likert scale, from 1 (total disagreement) to
7 (total agreement). The DAS-SF possesses good psycho-
metric properties in terms of model fit, reliability, and
convergent construct validity [69]. The DAS-SF has been
adapted to Romanian for the purposes of this study.
The Beliefs Scale (BS) [70] measures irrational beliefs.
It consists of 20 items, and responders indicate how
much they agree or disagree with each item using a five-
point Likert scale that ranges from 1 (strongly disagree)
to 5 (strongly agree). The BS shows good psychometric
properties regarding construct and discriminant validity
[71]. This scale has been translated into Romanian for
the purposes of this study.
The Automatic Thoughts Questionnaire (ATQ) [72] is
a 15-item self-report measure used to assess depression-
related cognitions. Participants rate, on a five-point
Likert scale from 1 (never) to 5 (almost all the time),
how frequently they have had a given thought over the
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past week. A higher score shows a higher frequency of
automatic thoughts. The psychometric properties of the
ATQ have been adequately demonstrated in previous
studies [73]. The ATQ has been successfully used previ-
ously on the Romanian population [74–76].
The Behavioral Activation for Depression Scale - Short
Form (BADS-SF) [77] is an instrument designed to be
administered weekly to measure changes in avoidance
and activation over the course of the Behavioral Activa-
tion (BA) treatment for depression. The BADS consists
of nine items grouped into two subscales (Activation
and Avoidance/Rumination). Respondents rate each
item on a seven-point Likert scale ranging from 0 (not
at all) to 6 (completely). The scale has good psychomet-
ric properties [78]. The BADS-SF has been translated
into Romanian for the purposes of this study.
Satisfaction with the Application Scale was specifically
designed for this study. It consists of 10 items that assess
users’ satisfaction with the application, its difficulty level,
attractiveness, and subjective utility. The first 8 items
are rated on a three-point scale, ranging from 0 to 2.
Each response scale is personalized to the content of the
item (e.g., How attractive did you find the exercises in-
cluded in the application? - 0 = rather unattractive, 1 =
attractive enough, 2 = very attractive). Item 9 assesses
the application globally, with the participant being
asked to give an overall grade between 1 (minimum)
and 10 (maximum). Item 10 asks the participants if
they would recommend the application to a friend
("yes" or "no").
The Application Use Scale was also developed specific-
ally for this study. It consists of 8 items that assess
weekly quantitative app usage aspects: the effort invested
in homework (1 item), number of practiced exercises (1
item), number of read courses (1 item), frequency of
general application use (1 item), and frequency of every
exercise use (4 items).
Two Romanian English-proficient post-doctoral clin-
ical psychologists, with good knowledge of the con-
structs measured, independently translated all the
instruments adapted into Romanian for the purposes of
the present study. Disagreements were resolved through
discussions between the translators. A senior clinical
psychologist and the principal investigator also reviewed
and approved the final versions.
Participant timeline
Possible participants are invited to access the study's
website [79] and, after carefully reading the information
package, they are instructed to create an online account.
The participants are then asked to answer a few demo-
graphic questions (i.e., report on their age, education,
status on the labor market, and marital/co-habitation
status) and complete the PHQ-9 to determine their
eligibility for further evaluation. If eligible, a screening
procedure is implemented. A short telephone interview
screens out those people whose interest in the study is
motivated by issues other than their mood (e.g., curios-
ity, practical/life problems, need for a psychological as-
sessment). Applicants who do not meet the inclusion
criteria are informed via email. They are thanked for
their interest, given a summary score and interpretation
for their PHQ-9 score, and encouraged to discuss their
problems with a professional, if necessary. Information
on how to reach a clinical psychologist or psychotherap-
ist is also provided.
Participants meeting inclusion criteria will be ran-
domly assigned to one of the two conditions: immediate
online intervention condition (mHealth intervention) or
the delayed-intervention condition (see the flow diagram
in Fig. 3). Subsequent assessments consist of all the
above instruments. Figure 4 shows the schedule of en-
rollment, interventions, and assessments.
The participants in the mHealth intervention are
assessed at pre-intervention (time 1, baseline), at mid-
intervention (time 2, 2 weeks after baseline), at post-
intervention (time 3, 4 weeks after baseline), and at 3,
6, and 12 months post-intervention (times 4, 5, and 6).
The participants in the delayed-intervention condition
are assessed before the waiting period (time 1, base-
line), at mid-waiting period (time 2, 2 weeks after
baseline), and at post-waiting period (time 3, 4 weeks
after baseline).
Participants assigned to the mHealth intervention will
be given access to the online application along with ex-
plicit instructions regarding the use of all of its sections.
Participants will be given 4 weeks to complete the inter-
vention, during which time weekly messages will be sent
out to them. Messages include regular assignments de-
signed for a complete and thorough use of the applica-
tion's courses and exercises, and encourage the review of
materials whenever possible. However, participants are
free to use the application at their own pace.
After each week, participants’ application use is evalu-
ated (see the Application Use Scale described above).
Similarly, after each week of using the application, the
participants are required to complete the CESD-R for
close monitoring of their depressive symptomatology
and individualized feedback on their emotional state.
Participants in the delayed intervention group are
placed on a wait list for 4 weeks.
Sample size
The sample size was estimated considering the explora-
tory nature of the two trials, in terms of investigating
the feasibility of the design and methodology employed,
as well as app-related usability aspects. As such, we
followed current research practice exploratory protocols.
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For example, in an audit of sample sizes for pilot and
feasibility trials being undertaken in the UK, Billingham,
Whitehead, and Julious [80] have found that the median
pilot study sample size for two-arm trials was 30 partici-
pants per arm, for continuous endpoints. Taking this
into consideration, as well as promising results (i.e., large
within-group effect sizes) reported by previous studies
testing mobile phone applications for depression [81], a
total number of 50 participants per study (i.e., 50 par-
ticipants without depressive symptomatology and 50
participants with mild depressive symptomatology) was
anticipated.
Recruitment
Possible participants are approached through presenta-
tions at various events and ads in the media. Additionally,
clinicians from the private practice area are contacted for
referrals. Those interested in using the application are
asked to provide their contact details and are subsequently
contacted via email, at which point the enrollment pro-
cedure is described.
Assignment to study group
The participants are assigned to one of the two trials,
depending on their depressive symptomatology level
(i.e., PHQ-9 score). Using the software Randomizer.org,
participants are then randomly distributed to one of
the trials’ conditions. Randomization is performed by a
research assistant using a simple (unrestricted)
randomization sequence that assigns two unique num-
bers per participant; the number assigned is either 1
or 2, according to the number of experimental condi-
tions. To conceal the allocation mechanism, the same
research assistant will monitor the assessments and
allow access to the application for the participants in
the wait-list control group, after 1 month. The princi-
pal investigator and the statisticians running the data
analysis will remain blinded to the study condition
until the completion of the study.
Data collection, management, and analyses
Data collection methods
The data are collected within the application, in the
Evaluation section, and transferred to our servers using
Fig. 3 CONSORT flow diagram [49] showing subject allocation to the study conditions
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an encrypted, secure (https) industry-standard transfer
protocol.
The following strategies will be implemented to pro-
mote participant retention and follow-up completion.
First of all, participants are reminded every week of the
specific assessment that needs to be completed, through
the Messages section, and are rewarded with more
”Energy” after completing it. Participants are also told
that the weekly completion of the mood question-
naires allows the app to create a personalized profile
of their mood (through the profile section) and, thus,
give individualized feedback on their emotional state.
Furthermore, the messages that the participants re-
ceive every week comprise gradual steps in covering
the app’s content and exercises — every message refers
to a new content and/or new exercise to be covered
during that week, explaining its purpose and possible
use, and, at the same time, encouraging the participant
to come back the next week. Lastly, for the follow-up
assessments, participants will receive new messages
reminding them that the free use of the app was pos-
sible because of a research grant, for which the collec-
tion of this data is essential.
Statistical methods
Improvement in the primary outcomes measures
scores within and between the groups (for each study)
will be examined using mixed-effects linear regression
analysis with a random intercept and slope over time
(three assessments: baseline, mid-intervention, post-
intervention) and fixed effects for intervention assign-
ment. The 3-, 6-, and 12-month follow-up data will
be analyzed in a separate fixed-effects model. The
main analysis will compare groups (experimental and
wait-list) in terms of cognitive vulnerability factors for
the first trial, or level of depressive symptoms for the
second trial. When analysis of secondary/other out-
comes is performed, the error probability will be ad-
justed according to the number of group comparisons
performed.
An intent-to-treat analysis will also be performed to
examine participants who dropped out prematurely.
App usage data and user activity will be examined in an
exploratory manner by comparing the participants’ self-
reported activity with their actual app usage as captured
by our software. This wealth of data will allow the possi-
bility of pinpointing any obstacles to user adherence to
Fig. 4 Schedule of enrollment, interventions, and assessments. *t1x and t2x represent weekly separate assessments
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the protocol, and will shed light on the reasons for drop-
outs or irregular usage patterns.
Monitoring study implementation
Two clinical psychologists, members of the study team,
screen for the risk of unintended effects or harm to the
participants (i.e., clinically significant increase in depres-
sive symptomatology, as measured by the CESD-R). The
psychologists monitor the weekly online evaluations and
clinically interpret the CESD-R score of every partici-
pant. If the participant does not complete the CESD-R
evaluation, she/he is contacted by telephone. If neces-
sary, the supervisor can decide to interrupt the partici-
pant's access to the application and make a further
referral.
Ethics and dissemination
The ethics commission at Babeș-Bolyai University has
approved this study. Although it does not involve the de-
livery of a treatment to depressed people, it does target
individuals with mild depressive symptomatology who
may be at risk for developing depression. Hence, there
are ethical concerns that need to be addressed. Firstly,
the initial screening process and the exclusionary criteria
single out people at risk for suicide, who are immediately
referred to the appropriate clinical care. Secondly, if a
participant’s condition worsens during the use of the
application, the clinical team can opt to interrupt his/
her access to the application and make a further refer-
ral or recommendation. Regarding confidentiality, spe-
cial attention has been given to securing the online
data collection and storage. Sensitive clinical data are
collected either through a web browser (during the
signup procedure) or from the mobile application. Both
these means communicate the data to the server over
industry-standard secure connections (i.e., https). The
server stores the data in a database that is not publicly
accessible. The system running our applications is kept
up to date to prevent intrusions. Access to the elec-
tronic data is password-protected, and the passwords
are changed regularly. The clinical screening reports
contain no personal identifying information.
Dissemination policy
Preliminary features of the application and its intended
purpose have been presented at several conferences, na-
tionally and internationally. Also, this research is being
promoted and constantly updated in terms of progress
and dissemination through its designated website [82].
The two trials’ results will be submitted for publication in
peer-reviewed journals, focusing on (1) feasibility and us-
ability results and (2) primary and secondary outcome re-
sults. New presentations at international conferences on
the topic of e-health solutions are also being considered.
Discussion
This exploratory study describes two randomized clinical
trials testing a smartphone app aimed at reducing cogni-
tive vulnerability and mild depressive symptoms, as risk
factors for the onset of depression. The two trials’ tar-
gets are (1) the general population and (2) a population
with minimal depressive symptoms. This research effort
is motivated by the global challenge that depression
raises. Depression prevalence and costs have continu-
ously increased over the years [1, 2, 4, 83]. Subthresh-
old depression also has a high prevalence [84, 85], is
associated with considerable individual and societal
costs [86, 87], and predicts future full-blown depressive
episodes [15, 88]. Depressive symptoms usually do not
remit without treatment [89], yet access to interven-
tions is limited [1], responses to available treatments
are suboptimal [19, 20], and recurrence rates are sub-
stantial [18]. Therefore, large-scale preventative strat-
egies before people experience depressive disorders
(when they are in need for full treatment) are needed.
To our knowledge, this is the first attempt to
capitalize on the ubiquity of smartphones to large-scale
dissemination of CBT-based strategies aimed at pre-
venting depression in non-clinical populations. By gen-
erating the first indirect evidence related to the
potential value of apps for preventing depression,
through decrease in cognitive vulnerability and reduc-
tion of depressive symptoms, this study can add sub-
stantially to the relatively small body of evidence
indicating that smartphone apps could be successfully
used to manage depression [35, 39, 90]. The app developed
for this study is designed to decrease general cognitive vul-
nerability and promote engagement in protective, adaptive
activities, while counteracting the tendency of premature
dropout (through gamification and customization). This
study capitalizes on targeting cognitive vulnerability factors
as mechanisms of change. Notably, studies conducted until
now have focused almost exclusively on testing the apps
clinical efficacy in decreasing symptoms. The investigation
of the mechanisms of change in relation to technologically
mediated CBT preventive/intervention strategies seems to
be grossly under-investigated. By including two types of
samples recruited from a general, non-clinical population
(i.e., symptom-free participants, and participants showing
minimal symptoms of depression, respectively), this re-
search may be able to add support to the assumption that
symptoms remission/lowering is explained by a decrease
in cognitive vulnerability [25]. Although the study design
does not allow the provision of irrefutable support for such
an assumption, the results do have the potential of guiding
future research.
There are, however, limitations of this study. The main
one is related to the control group. Ideally, an active pla-
cebo control should be included. Yet, because there are
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no studies investigating the potential utility of apps in
preventing depressive symptoms in a non-clinical popu-
lation, a simple wait-list control was included. Neverthe-
less, this implies that, if the expected results are
obtained, the possibility that they are explained by the
simple usage of the app, rather than the app content,
will not be ruled out. However, because a decrease in
symptoms is not the main or the sole indicator of the
app’s efficacy but, rather, may be a possible change in
cognitive vulnerability factors in a population free of
marked psychological distress, the authors believe that
the simple usage of the app is unlikely to explain even-
tual positive results. However, future studies should
strive to contrast the “active” app with a “sham” app (i.e.,
an alternative app which looks similar, but does not tar-
get cognitive vulnerability factors associated with depres-
sion) in order to derive firm conclusions.
Trial status
Participant recruitment began on 7 June 2016. Rando
mization of the participants was performed on 15 June
2016.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 122 kb)
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